Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with retinoic acid in malignant melanoma.

被引：0
|
作者：
Kato, Y
Wang, XF
Qian, DZ
Wei, YF
Zhang, L
Atadja, P
Pili, R
机构：
[1] Johns Hopkins Univ, Baltimore, MD 21218 USA
[2] Novartis Pharma AG, Basel, Switzerland
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6253S / 6253S
页数：1
相关论文
共 50 条
  • [21] A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors
    Rowinsky, EK
    Pacey, S
    Patnaik, A
    O'Donnell, A
    Mita, MM
    Atadja, P
    Peng, B
    Dugan, M
    Scott, JW
    De Bono, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 200S - 200S
  • [22] Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies
    Rowinsky, EK
    de Bono, J
    Deangelo, DJ
    van Oosterom, A
    Morganroth, J
    Laird, GH
    Dugan, M
    Scott, JW
    Ottmann, OG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 224S - 224S
  • [23] Effect of the histone deacetylase inhibitor valproic acid in combination with all-trans retinoic acid on normal and malignant hematopoiesis.
    Guel, H
    Wassmann, B
    Romanski, A
    Hoelzer, D
    Ruthardt, M
    Ottmann, OG
    Bug, G
    BLOOD, 2003, 102 (11) : 626A - 627A
  • [24] Preclinical evaluation of the effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells.
    Hurtubise, Annie
    Momparler, Richard L.
    CANCER RESEARCH, 2006, 66 (08)
  • [25] LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma:: Results of a pre-clinical evaluation in vitro and in vivo.
    Catley, L
    Weisberg, E
    Tai, YT
    Lin, B
    Mitsiades, N
    Hideshima, T
    LeBlanc, R
    Shringapure, R
    Burger, R
    Mitsiades, C
    Chauhan, D
    Schlossman, R
    Munshi, N
    Richardson, P
    Griffin, J
    Anderson, K
    BLOOD, 2002, 100 (11) : 106A - 106A
  • [26] The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
    Grant, S
    LEUKEMIA, 2004, 18 (12) : 1931 - 1933
  • [27] The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
    S Grant
    Leukemia, 2004, 18 : 1931 - 1933
  • [28] Antitumor effects of zoledronic acid in combination with histone deacetylase inhibitor valproic acid
    Strauss, Arne
    Loertzer, Hagen
    Ringert, Rolf-Hermann
    Thelen, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3
    Bali, P
    George, P
    Cohen, P
    Tao, JG
    Guo, F
    Sigua, C
    Vishvanath, A
    Scuto, A
    Annavarapu, S
    Fiskus, W
    Moscinski, L
    Atadja, P
    Bhalla, K
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 4991 - 4997
  • [30] The Histone Deacetylase Inhibitor LAQ824 Maintains Normal Hematopoietic Progenitor cells (HPC) Associated with Induction of Notch Target Genes and Does Not Eliminate Leukemic HPC in Vitro
    Schwarz, Kerstin
    Ottmann, Oliver
    Romanski, Annette
    Vogel, Anja
    Scott, Jeffrey W.
    Serve, Hubert
    Bug, Gesine
    BLOOD, 2008, 112 (11) : 486 - 487
12345